Laboratorios Farmaceuticos Rovi, S.A. (LON: 0ILL)

Laboratorios Farmaceuticos Rovi Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	799.25	829.51	817.7	648.68	419.96	381.31
Revenue Growth (YoY)	-4.52%	1.44%	26.06%	54.46%	10.14%	25.76%
Cost of Revenue	310.33	346.17	305.27	268.84	182.83	169.88
Gross Profit	488.92	483.34	512.43	379.84	237.14	211.43
Selling, General & Admin	154.59	147.02	129.99	103.36	84.83	92.22
Other Operating Expenses	94.66	92.52	105.84	74.96	57.8	58.96
Operating Expenses	276.35	263.87	258.69	199.68	162.22	169.4
Operating Income	212.57	219.47	253.74	180.15	74.92	42.03
Interest Expense	-3.05	-0.95	-0.85	-0.91	-1.07	-0.65
Interest & Investment Income	-	0.01	0.01	0.07	0	0.05
Earnings From Equity Investments	-0.1	-0.13	0.2	0.18	-0.03	-0.2
Currency Exchange Gain (Loss)	0.23	-0.09	-0.82	-0.18	0.04	-0.05
Other Non Operating Income (Expenses)	2.08	2.09	3.93	3.4	0.12	1.03
EBT Excluding Unusual Items	211.73	220.41	256.21	182.72	73.98	42.22
Gain (Loss) on Sale of Investments	-	-	1.76	-	-	-
Asset Writedown	-	-	-0	-0.1	-0.06	-0.34
Other Unusual Items	-	-	-	-	-1.34	-
Pretax Income	211.73	220.41	257.97	182.63	72.58	41.88
Income Tax Expense	46.77	50.11	58.3	29.55	11.52	2.61
Earnings From Continuing Operations	164.96	170.3	199.67	153.08	61.06	39.27
Minority Interest in Earnings	0.04	0.04	0	-	-	-
Net Income	165	170.34	199.67	153.08	61.06	39.27
Net Income to Common	165	170.34	199.67	153.08	61.06	39.27
Net Income Growth	-16.24%	-14.69%	30.44%	150.71%	55.47%	119.46%
Shares Outstanding (Basic)	53	53	53	55	55	55
Shares Outstanding (Diluted)	53	53	53	55	55	55
Shares Change (YoY)	-	-0.51%	-3.50%	0.03%	0.37%	7.73%
EPS (Basic)	3.09	3.20	3.73	2.76	1.10	0.71
EPS (Diluted)	3.09	3.20	3.73	2.76	1.10	0.71
EPS Growth	-	-14.25%	35.31%	150.37%	54.89%	103.73%
Free Cash Flow	65.86	59.45	186.88	109.22	7.54	-34.94
Free Cash Flow Per Share	1.23	1.12	3.50	1.97	0.14	-0.63
Dividend Per Share	-	1.104	1.294	0.956	0.381	0.175
Dividend Growth	-	-14.69%	35.39%	150.68%	117.70%	119.42%
Gross Margin	61.17%	58.27%	62.67%	58.56%	56.47%	55.45%
Operating Margin	26.60%	26.46%	31.03%	27.77%	17.84%	11.02%
Profit Margin	20.64%	20.53%	24.42%	23.60%	14.54%	10.30%
Free Cash Flow Margin	8.24%	7.17%	22.85%	16.84%	1.80%	-9.16%
EBITDA	233.89	238.02	271.33	196.56	89.61	55.44
EBITDA Margin	29.26%	28.69%	33.18%	30.30%	21.34%	14.54%
D&A For EBITDA	21.31	18.54	17.59	16.41	14.69	13.41
EBIT	212.57	219.47	253.74	180.15	74.92	42.03
EBIT Margin	26.60%	26.46%	31.03%	27.77%	17.84%	11.02%
Effective Tax Rate	22.09%	22.73%	22.60%	16.18%	15.88%	6.22%
Advertising Expenses	-	21.75	19.99	12.71	11.41	19.53

Source: S&P Capital IQ. Standard template. Financial Sources.